Document is current
Any future updates will be listed below
-
Authors
Brzdęk, Michał https://orcid.org/0000-0002-1180-9230
Zarębska-Michaluk, Dorota
Kukla, Michał
Janocha-Litwin, Justyna
Dybowska, Dorota
Janczewska, Ewa
Lorenc, Beata
Berak, Hanna
Mazur, Włodzimierz
Tudrujek-Zdunek, Magdalena
Klapaczyński, Jakub
Piekarska, Anna
Sitko, Marek
Laurans, Łukasz
Parfieniuk-Kowerda, Anna
Flisiak, Robert
- License Information
-
More Information
Article History
Received: 3 May 2024
Revised: 11 August 2024
Accepted: 12 August 2024
First Online: 20 August 2024
Declarations
:
: Brzdęk M has no conflict of interest to declare. Zarębska-Michaluk D has acted as a speaker for AbbVie and Gilead. Kukla M has no conflict of interest to declare. Janocha-Litwin J has no conflict of interest to declare. Dybowska D has received funding for participation in the conference from AbbVie. Janczewska E has acted as a speaker and/or advisor for AbbVie, Gilead, MSD, Ipsen, and has received funding for clinical trials from AbbVie, Allergan, BMS, Celgene, Cymabay, Dr Falk Pharma, Exelixis, GSK, and MSD. Lorenc B has no conflict of interest to declare. Berak H has acted as a speaker and/or advisor for Gilead, Abbvie, and MSD. Mazur W has acted as a speaker and/or advisor for AbbVie, Gilead, Merck, and has received funding for clinical trials from AbbVie, Gilead, and Janssen. Tudrujek-Zdunek M has no conflict of interest to declare. Klapaczyński J has acted as a speaker for Gilead and AbbVie. Piekarska A has acted as a speaker and/or advisor for AbbVie, Gilead, Merck, and Roche. Sitko M has no conflict of interest to declare. Laurans Ł has no conflict of interest to declare. Parfieniuk-Kowerda A has no conflict of interest to declare. Flisiak R has acted as a speaker and/or advisor, and has received funding for clinical research from AbbVie, Gilead, Merck, and Roche.
